Open-label cohort of the phase 3 SYMPATICO trial: first-line ibrutinib plus venetoclax in 78 patients with nonblastoid mantle cell lymphoma aged ≥65 or with TP53 mutation achieved 69% complete response, median PFS 40.2 months, 3-year OS 79%; no comparator arm.
RCTn = 78
Wang et al. First-line ibrutinib plus venetoclax for nonblastoid mantle cell lymphoma in patients ≥65 years old or with TP53 mutations